Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Thomas Goedecke und 8 weiteren Autor:innen. Beteiligte Einrichtung: European Medicines Agency, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: European Union, Pharmacovigilance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) launched a strategy to examine the public health impact of major regulatory interventions aimed at minimising risks of medicinal products. We conducted a lessons learnt analysis of impact studies completed between 2015 and 2023.
Methods
We surveyed PRAC Sponsors and (Co‐)Rapporteurs involved in the evaluation of 12 impact studies (10 commissioned by EMA and 2 conducted collaboratively by Member States) to explore how these support regulatory decision‐making. Questions covered achievement of study objectives, risk minimisation effectiveness, added value for regulatory decision‐making, and recommendations for future impact studies. Themes were generated using thematic content analysis.
Results
Survey responses from 15 PRAC Sponsors and (Co‐)Rapporteurs from 10 European Union Member States were included in the analysis. Among four cross‐sectional surveys and eight drug utilisation studies, 50% achieved all objectives, the other studies partially due to limitations. Two studies concluded that risk minimisation measures were overall effective, two were effective with variation across countries, two were partially effective and four studies showed limited effectiveness. Two studies were deemed inconclusive due to limitations. The reasons for the limited effectiveness of risk minimisation may be explored using mixed‐method approaches. Assessment of study feasibility and a priori discussion of effectiveness measurements is important.
Conclusion
Despite limitations, impact research adds value to regulatory decision‐making by addressing knowledge gaps and providing additional information on unintended consequences of regulatory interventions. Our recommendations will help to improve planning, conducting and interpretating future impact studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- European Medicines Agency, Amsterdam, The Netherlands.
- Medicines Evaluation Board, Utrecht, The Netherlands.
- French National Agency for Medicines and Health Products Safety (ANSM), Saint-Denis, France.
- Federal Institute for Drugs and Medical Devices, Bonn, Germany.
- Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands.
ORCID-Profile: Thomas Goedecke, Liana Martirosyan, Nathalie Gault, Karin Seifert, Daniel R Morales, Priya Bahri, Valerie Strassmann, Martin Huber, Sabine Straus
Zitieren
APA
Goedecke, T., Martirosyan, L., Gault, N., Seifert, K., Morales, D. R., Bahri, P., Strassmann, V., Huber, M., & Straus, S. (2024). Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5874
Vancouver
Goedecke T, Martirosyan L, Gault N, Seifert K, Morales DR, Bahri P, et al. Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5874
BibTeX
@article{Goedecke2024,
author = {Goedecke, Thomas and Martirosyan, Liana and Gault, Nathalie and Seifert, Karin and Morales, Daniel R and Bahri, Priya and Strassmann, Valerie and Huber, Martin and Straus, Sabine},
title = {Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5874}
}
EUVIMED